Bordeaux, France / March 1st, 2022 – TreeFrog Therapeutics, a French-based biotech aimed at making safer, more efficient and more affordable off-the-shelf cell therapies based on induced pluripotent stem cells (iPSCs), today announces the formation of its Scientific Advisory Board (SAB). Bringing together world-class experts in biophysics, pluripotent stem cell biology and gene editing, the newly created SAB will guide the development of proprietary C-StemTM technology platform and in-house cell therapy programs. [Read more…]
FDA Grants Orphan Drug Designation to Celularity’s CYNK-101, an NK Cell Therapy for GI Cancers
CYNK-101 is an investigational genetically modified NK cell therapy designed to synergize with antibody therapeutics for difficult to treat cancers of high unmet medical need
Phase 1/2a clinical trial will evaluate the safety and preliminary efficacy of CYNK-101 in combination with standard chemotherapy, trastuzumab, and pembrolizumab
5th designation received by Celularity within 12 months from the US FDA
Ageless Biotech Announces FDA Accepted Phase IIb Study Targeting Moderate to Severe Osteoarthritis of the Knee Joint
February 18, 2022, Sheridan, WY — Ageless Biotech, Inc., a biotech company created to bring stem cell-based therapeutics to market, has acquired a U.S. Food and Drug Administration (FDA) Investigational New Drug Application (IND) for the treatment of Osteoarthritis of the Knee.
The Arthritis Foundation has described Osteoarthritis as a “chronic disease … with no cure.” Over a decade ago in 2009 ABC News published, medical care for osteoarthritis patients in the United States costs $185.5 billion a year.1 [Read more…]
EdiGene and Neukio to Develop iPSC-Derived NK Cell Therapies
Feb. 9, 2022, BEIJING & SHANGHAI & CAMBRIDGE, Mass. – EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious genetic diseases and cancer, and Neukio Biotherapeutics, a biotechnology company focused on the development and commercialization of allogenic iPSC-CAR-NK cell therapies, today announced an R&D collaboration to develop next-generation immune cell therapies. [Read more…]
Exopharm Signs Master Collaborative Agreement to Manufacture Exosomes for Astellas
-
Astellas Institute for Regenerative Medicine (AIRM) is a subsidiary of Astellas Pharma Inc., a top 20 global pharmaceutical company
-
Initial services will seek to validate Exopharm’s LEAP, LOAD and EVPS technology platforms to manufacture exosomes for Astellas, firstly at Exopharm’s facilities in Melbourne followed by the Astellas facilities in Massachusetts USA
-
Future potential collaboration is anticipated following validation
-
This is Exopharm’s first collaboration services agreement with a major pharmaceutical company
- « Previous Page
- 1
- …
- 61
- 62
- 63
- 64
- 65
- …
- 116
- Next Page »